Fetal Blood Group Genotyping

@article{Daniels2006FetalBG,
  title={Fetal Blood Group Genotyping},
  author={Geoff L Daniels and Kirstin M Finning and Pete Martin and Joanna Summers},
  journal={Annals of the New York Academy of Sciences},
  year={2006},
  volume={1075}
}
Abstract:  Prediction of fetal blood group from DNA is usually performed when the mother has antibodies to RhD, to assess whether the fetus is at risk from hemolytic disease of the fetus and newborn (HDFN). Over the last five years RhD testing on fetal DNA in maternal plasma has been introduced. At the International Blood Group Reference Laboratory (IBGRL) we employ real‐time quantitative polymerase chain reaction (RQ‐PCR) to detectRHDexons 4, 5, and 10, which also revealsRHDψ. SRYand, in RhD… 
Fetal RHD genotyping by analysis of maternal plasma in a mixed population
TLDR
The findings indicate that the accuracy of RHD gene using three regions (exons 4, 5, and 10) can be sufficient for clinical application in a multi‐ethnic population.
The use of maternal plasma for prenatal RhD blood group genotyping.
TLDR
Fetal D typing has become the standard of care in England in pregnant women with a significant level of anti-D and is performed by detection of an RHD gene in cell-free DNA in the plasma of D-negative pregnant women.
Fetal RHD Genotyping from Circulating Cell-Free Fetal DNA in Plasma of Rh Negative Pregnant Women in Iran
TLDR
The present study confirms the precision of fetal RHD and SRY genotyping in maternal plasma by real-time PCR technique and helps RhD negative pregnant women about the appropriate use of anti-D immunoglobulin and also on the management and prevention of HDFN.
Effect of high throughput RHD typing of fetal DNA in maternal plasma on use of anti-RhD immunoglobulin in RhD negative pregnant women: prospective feasibility study
TLDR
High throughput RHD genotyping of fetuses in all RhD negative women is feasible and would substantially reduce unnecessary administration of anti-RhD immunoglobulin to RhD positive pregnant women with an RhDnegative fetus.
Non-invasive prenatal determination of fetal RhD genotyping from maternal plasma: a preliminary study in Pakistan.
TLDR
These preliminary results demonstrate the feasibility of non-invasive pre-natal diagnosis of fetal RhD status of D-negative mothers in Pakistan.
Fetal RhD genotyping: a more efficient use of anti-D immunoglobulin.
Noninvasive fetal RhD genotyping.
  • F. B. Clausen, M. B. Damkjær, M. Dziegiel
  • Medicine
    Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
  • 2014
Non-invasive fetal RHD genotyping
TLDR
F fetal RhD genotyping enables antenatal prophylaxis to be targeted to only those women carrying a D-positive fetus to avoid unnecessary treatment, and is widely used to assess the risk of HDFN in anti-D immunized women.
Prenatal testing for hemolytic disease of the newborn and fetal neonatal alloimmune thrombocytopenia – current status
  • N. Avent
  • Medicine
    Expert review of hematology
  • 2014
TLDR
Prenatal testing using initially fetal DNA obtained from invasively obtained amniotic fluid or chorionic villus evolved into testing using maternal plasma as source of fetal DNA, and this is in routine use as a safe non-invasive diagnostic that has no risk to the fetus of alloimmunization or spontaneous miscarriage.
Red cell genotyping and the future of pretransfusion testing.
TLDR
Routine use of DNA-based extended phenotyping to provide optimally matched donations for patients with preexisting antibodies or patients with a known predisposition to alloimmunization, such as those with sickle cell disease, is widely used.
...
1
2
3
4
...

References

SHOWING 1-10 OF 17 REFERENCES
A Clinical Service in the UK to Predict Fetal Rh (Rhesus) D Blood Group Using Free Fetal DNA in Maternal Plasma
TLDR
Investigation of fetal RHD sequences in maternal plasma may allow anti‐D to be restricted to pregnancies involving a D‐positive fetus, and the new test has significantly reduced the number of invasive procedures carried out in the UK for fetal D grouping.
Report of the First International Workshop on molecular blood group genotyping
TLDR
A consensus arising from discussion on the workshop results between participants at a feedback meeting and by e‐mail has resulted in seven recommendations for molecular blood group genotyping.
Prediction of fetal D status from maternal plasma: introduction of a new noninvasive fetal RHD genotyping service
TLDR
The detection of RHD sequences in maternal plasma has been used to predict fetal D status, based on the assumption that RHD is absent in D– genomes, and this data indicates that this assumption is likely to be correct.
The presence of an RHD pseudogene containing a 37 base pair duplication and a nonsense mutation in africans with the Rh D-negative blood group phenotype.
TLDR
Existing PCR-based methods for predicting D phenotype from DNA are not suitable for testing Africans or any population containing a substantial proportion of people with African ethnicity, so a new test is developed that detects the 37 bp insert in exon 4 of RHDpsi.
The presence of an RHD pseudogene containing a 37 base pair duplication and a nonsense mutation in Africans with the Rh D-negative blood group phenotype
TLDR
Existing PCR-based methods for predicting D phenotype from DNA are not suitable for testing Africans or any population containing a substantial proportion of people with African ethnicity, so a new test is developed that detects the 37 bp insert in exon 4 of RHD ψ.
Quantitative assessment of hematopoietic chimerism after bone marrow transplantation by real-time quantitative polymerase chain reaction.
TLDR
This new assay provides an accurate quantitative assessment of mixed chimerism that can be useful in guiding early implementation of additional treatments in hematopoietic stem cell transplantation.
Genotype-phenotype correlations: assessing the influence of sequence variants on the clinical phenotype.
It used to be simple. Physicians observed patients, asked questions, examined them, and established a defined clinical phenotype. Sometimes a laboratory analyte, with a sufficient and significant
Molecular background of VS and weak C expression in blacks
BACKGROUND: The Rh system is complex and consists of as many as 45 different antigens. Red cells of about 25 percent of the black population carry VS an Rh‐system antigen (Rh20), but this antigen is
LNA: a versatile tool for therapeutics and genomics.
Human Blood Groups
TLDR
Blood Groups in Man, by Dr. R. R Race and Dr. Ruth Sanger, 1950 is published.
...
1
2
...